The Global Burden of Cancer 2013 Global Burden of Disease Cancer Collaboration

Imagem de Miniatura
Arquivos
art_FITZMAURICE_The_Global_Burden_of_Cancer_2013_Global_Burden_2015.PDF (9.77 MB)
Citações na Scopus
2370
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER MEDICAL ASSOC
Autores
FITZMAURICE, Christina
DICKER, Daniel
PAIN, Amanda
HAMAVID, Hannah
MORADI-LAKEH, Maziar
MACLNTYRE, Michael F.
ALLEN, Christine
HANSEN, Gillian
WOODBROOK, Rachel
WOLFE, Charles
Citação
JAMA ONCOLOGY, v.1, n.4, p.505-527, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IMPORTANCE Cancer is among the leading causes of death worldwide. Current estimates of cancer burden in individual countries and regions are necessary to inform local cancer control strategies. OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex from 1990 to 2013. EVIDENCE REVIEW The general methodology of the Global Burden of Disease (GBD) 2013 study was used. Cancer registries were the source for cancer incidence data as well as mortality incidence (MI) ratios. Sources for cause of death data include vital registration system data, verbal autopsy studies, and other sources. The MI ratios were used to transform incidence data to mortality estimates and cause of death estimates to incidence estimates. Cancer prevalence was estimated using MI ratios as surrogates for survival data; YLDs were calculated by multiplying prevalence estimates with disability weights, which were derived from population-based surveys; YLLs were computed by multiplying the number of estimated cancer deaths at each age with a reference life expectancy; and DALYs were calculated as the sum of YLDs and YLLs. FINDINGS In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries. CONCLUSIONS AND RELEVANCE Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening, treatment, and palliation.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21255
Referências
  1. Ahn HS, 2014, NEW ENGL J MED, V371, P1765, DOI 10.1056/NEJMp1409841
  2. Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
  3. BEASLEY RP, 1981, LANCET, V2, P1129
  4. Campos NG, 2012, INT J CANCER, V130, P2672, DOI 10.1002/ijc.26269
  5. CHEN CJ, 1991, HEPATOLOGY, V13, P398, DOI 10.1016/0270-9139(91)90289-8
  6. Cho E, 2011, ARCH INTERN MED, V171, P1487, DOI 10.1001/archinternmed.2011.356
  7. Chow WH, 2000, NEW ENGL J MED, V343, P1305, DOI 10.1056/NEJM200011023431804
  8. Coleman MP, 2003, ANN ONCOL, V14, pV128, DOI 10.1093/annonc/mdg756
  9. Craig BM, 2012, CANCER EPIDEM BIOMAR, V21, P474, DOI 10.1158/1055-9965.EPI-11-1087
  10. Curado M. P., 2007, CANC INCIDENCE 5 CON, V9
  11. Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020
  12. Di Cesare M, 2013, LANCET, V381, P585, DOI 10.1016/S0140-6736(12)61851-0
  13. Doll R, 1966, CANC INCIDENCE 5 CON, V1
  14. Doll R, 1970, CANC INCIDENCE 5 CON, VII
  15. Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509
  16. Ellis L, 2014, INT J CANCER, V135, P1774, DOI 10.1002/ijc.28990
  17. Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6
  18. Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1
  19. Forman D, 2013, CANC INCIDENCE 5 CON, VX
  20. GBD 2013 Disease and Injury Incidence and Prevalence Collaborators, LANCET IN PRESS
  21. Griffiths UK, 2005, HEALTH POLICY PLANN, V20, P50, DOI 10.1093/heapol/czi006
  22. Ho AS, 2015, CANCER-AM CANCER SOC, V121, P1793, DOI 10.1002/cncr.29289
  23. Hunt JD, 2005, INT J CANCER, V114, P101, DOI 10.1002/ijc.20618
  24. Khanna A, 2013, CLIN OTOLARYNGOL, V38, P103, DOI 10.1111/coa.12047
  25. Kilander C, 2014, ACTA ONCOL, V53, P822, DOI 10.3109/0284186X.2013.857429
  26. Lambe M, 2011, ACTA ONCOL, V50, P1220, DOI 10.3109/0284186X.2011.599338
  27. Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
  28. Lozano R, 2013, LANCET, V381, P628
  29. Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
  30. MANDEL JS, 1995, INT J CANCER, V61, P601, DOI 10.1002/ijc.2910610503
  31. Ng M, 2014, JAMA-J AM MED ASSOC, V311, P183, DOI 10.1001/jama.2013.284692
  32. Muir C, 1987, CANC INCIDENCE 5 CON, VV
  33. Murray CJL, 2013, LANCET, V381, P628
  34. Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4
  35. Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6
  36. Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
  37. Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
  38. Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
  39. Pampel F, 2008, SOC SCI MED, V66, P1772, DOI 10.1016/j.socscimed.2007.12.003
  40. Pandeya N, 2016, CLIN ENDOCRINOL, V84, P257, DOI 10.1111/cen.12724
  41. Parkin DM, 2009, EUR J CANCER, V45, P756, DOI 10.1016/j.ejca.2008.11.033
  42. Parkin DM, 1997, CANC INCIDENCE 5 CON, VVII
  43. Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI
  44. Parkin DM, 2002, CANC INCIDENCE 5 CON, VVIII
  45. Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013
  46. Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8
  47. Salomon JA, 2012, LANCET, V380, P2144, DOI 10.1016/S0140-6736(12)61690-0
  48. Sankaranarayanan R, 2005, INT J CANCER, V116, P617, DOI 10.1002/ijc.21050
  49. Sankaranarayanan R, 2004, INT J CANCER, V109, P461, DOI 10.1002/ijc.11726
  50. Sankaranarayanan R, 2013, VACCINE, V31, pF47, DOI 10.1016/j.vaccine.2012.06.066
  51. Sauvaget C, 2011, INT J GYNECOL OBSTET, V113, P14, DOI 10.1016/j.ijgo.2010.10.012
  52. Seow A, 2000, CANCER EPIDEM BIOMAR, V9, P1215
  53. Subbaraman N, 2014, NATURE, V513, pS16, DOI 10.1038/513S16a
  54. Suwanrungruang K, 2011, ASIAN PAC J CANCER P, V12, P3283
  55. TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501
  56. Tu HAT, 2009, EXPERT REV VACCINES, V8, P907, DOI [10.1586/erv.09.53, 10.1586/ERV.09.53]
  57. Vos T, 2013, LANCET, V381, P628
  58. Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
  59. Wang HD, 2014, LANCET, V384, P957, DOI 10.1016/S0140-6736(14)60497-9
  60. Wang HD, 2012, LANCET, V380, P2071, DOI 10.1016/S0140-6736(12)61719-X
  61. Wang XR, 2009, ANN ONCOL, V20, P746, DOI 10.1093/annonc/mdn699
  62. Waterhouse J, 1982, CANC INCIDENCE 5 CON, VIV
  63. Waterhouse J, 1976, CANC INCIDENCE 5 CON, VIII
  64. World Health Organization, 2014, COMPR CERV CANC CONT
  65. Yin ZH, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0114-5
  66. Yu ITS, 2006, CANCER RES, V66, P4961, DOI 10.1158/0008-5472.CAN-05-2932
  67. Yuen MF, 2009, J HEPATOL, V50, P80, DOI 10.1016/j.jhep.2008.07.023

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03